We bring you the latest news from the healthcare about the health care in the United Kingdom. Do your have news for us? Contact the editor. Watch also this special movie.

vrijdag 28 april 2017

Nature Reviews Drug Discovery contents May 2017 Volume 16 Number 5 pp 297-367

If you are unable to see the message below, click here to view.

Nature Reviews Drug Discovery


Advertisement
IMMUNE PROFILING IN HEALTH AND DISEASE 

September 17-19, 2017 | Seattle, WA, USA

Presented by: Adaptive Biotechnologies | Nature Immunology | Nature Medicine | Nature Biotechnology

REGISTER NOW!
 
TABLE OF CONTENTS
 
May 2017 Volume 16 Number 5Advertisement
Nature Reviews Drug Discovery cover
2015 2-year Impact Factor 47.120 Journal Metrics 2-year Median 31
In this issue
Comment
News and Analysis
Research Highlights
Reviews
Correction

Also this month
 Featured article:
Strategies and challenges for the next generation of antibody–drug conjugates
Alain Beck, Liliane Goetsch, Charles Dumontet & Nathalie Corvaïa
 

Genomics has met its match!
 
MAKE MORE MEANINGFUL CONNECTIONS

A powerful first-line phenotypin
g technology delivering a readout of the molecular phenotype and all its influences, both genetic and non-genetic.

See how genomics and metabolomics are breaking through together.
Subscribe
 
Facebook
 
RSS
 
Recommend to library
 
Twitter
 
Advertisement

BIOPHARMA DEALMAKERS
BioPharma DealmakersCompany Profiles and Partnering Opportunities

 
Advertisement
IBS-NATURE CONFERENCE ON FRONTIERS IN GENOME ENGINEERING 

September 27-29, 2017 | Seoul, Korea

Presented by: Institute for Basic Science | Institute of Genetics and Developmental Biology, CAS | Nature | Nature Biotechnology

REGISTER NOW!
 
Advertisement
REGENERATION 2017
Presented by: Ospedale San Raffaele | Nature

The conference will feature sessions on regeneration in animal models, functional and dysfunctional regeneration in mammals, and new therapeutic approaches to regeneration.

November 16-18, 2017 | Milan, Italy
REGISTER NOW!
 
Comment: Accelerating development of scientific evidence for medical products within the existing US regulatory framework
Rachel E. Sherman, Kathleen M. Davies, Melissa A. Robb, Nina L. Hunter & Robert M. Califf
p297 | doi:10.1038/nrd.2017.25
Growing access to diverse 'real-world' data sources is enabling new approaches to close persistent evidence gaps about the optimal use of medical products in real-world practice. Here, we argue that contrary to widespread impressions, existing FDA regulations embody sufficient flexibility to accommodate the emerging tools and methods needed to achieve this goal.
Abstract | Full Text | PDF | Supplementary information
 
NEWS AND ANALYSISTop
Nine paths to PCSK9 inhibition
Asher Mullard
p299 | doi:10.1038/nrd.2017.83
A lipid-modulating protein that exemplifies the value of human genetics for target validation has provided a fertile testing ground for new drug modalities including long-acting RNA interference drugs, vaccines against self-antigens, CRISPR therapeutics and small molecules that control ribosomal activity.
PDF
CAR T therapies drive into new terrain
Katie Kingwell
p301 | doi:10.1038/nrd.2017.84
The FDA could soon approve the first chimeric antigen receptor (CAR) T therapies for blood cancers, but this young field is still working on how to address solid tumours, safety concerns and manufacturing issues.
PDF
NEWS IN BRIEF
FDA approves first drug for primary progressive multiple sclerosis
Asher Mullard
p305 | doi:10.1038/nrd.2017.88
PDF
FDA approves first deuterated drug
Asher Mullard
p305 | doi:10.1038/nrd.2017.89
PDF
FDA approves dupilumab for severe eczema
Asher Mullard
p305 | doi:10.1038/nrd.2017.90
PDF
BIOBUSINESS BRIEFS
Regulatory watch: From big data to smart data: FDA's INFORMED initiative
Sean Khozin, Geoffrey Kim & Richard Pazdur
p306 | doi:10.1038/nrd.2017.26
PDF
BIOBUSINESS BRIEFS
Trial watch: Trends in clinical trial design complexity
Kenneth A. Getz & Rafael A. Campo
p307 | doi:10.1038/nrd.2017.65
PDF
AN AUDIENCE WITH
Thomas Lynch
p308 | doi:10.1038/nrd.2017.69
Thomas Lynch, Bristol-Myers Squibb's new Chief Scientific Officer, discusses his R&D priorities, genomics diagnostics and the need for faster development of novel cancer drugs in earlier stages of disease.
PDF
FROM THE ANALYST'S COUCH
Trends in the market for antihypertensive drugs
M. Adam Ali, Salman Rizvi & Basharut A. Syed
p309 | doi:10.1038/nrd.2016.262
This analysis provides an overview of novel antihypertensive products, many of which are fixed-dose combinations of different drug classes, and provides an outlook on their likely impact on the market.
PDF
RESEARCH HIGHLIGHTSTop

Analgesia: Designing out opioid side effects
p311 | doi:10.1038/nrd.2017.68
PDF


Metabolic Disease: Protein tyrosine phosphatase inhibitor reverses diabetes
p312 | doi:10.1038/nrd.2017.73
PDF


Cancer: Belt and braces for BCR-ABL
p312 | doi:10.1038/nrd.2017.79
PDF


Anticancer therapy: Re-educating macrophages
p313 | doi:10.1038/nrd.2017.82
PDF


Regenerative medicine: Targeting adaptor protein interactions for nerve regrowth
p314 | doi:10.1038/nrd.2017.85
PDF



IN BRIEF

Antibiotics: Reversing resistance | Viral infections: Targeting host kinases | Cancer: Identifying synergistic drug combinations | G protein-coupled receptors: Novel probe for MRGPRX2
PDF

Drug Discovery
JOBS of the week
Head of Functional Characterization (m / f)
Roche Diagnostics GmbH
Program Director CART Cell
Servier
Sr. Scientific Researcher, NMR Spectroscopy - Structural Biology
Genentech, Inc.
Senior Scientist – Computational Medicinal Chemist
Philip Morris International (PMI)
Associate Director, Oncology In Vivo Pharmacology
Janssen Pharmaceutica
More Science jobs from
Drug Discovery
EVENT
Microbiome Drug Development Summit
27.06.17
Boston, USA
More science events from
Advertisement
Confident Protein/Peptide Sequencing

Shimadzu's protein sequencers offer increased sensitivity to enable the study of longer protein sequences, more stable retention times, and reduced liquid waste/running costs. New software enables compliance with FDA 21 CFR Part 11 guidelines, while easy-to-use data analysis functions simplify operation, data processing and reporting.

Learn more.
 
REVIEWSTop
Strategies and challenges for the next generation of antibody-drug conjugates
Alain Beck, Liliane Goetsch, Charles Dumontet & Nathalie Corvaia
p315 | doi:10.1038/nrd.2016.268
Antibody-drug conjugate (ADCs), which aim to target highly cytotoxic drugs specifically to cancer cells, are one of the fastest growing classes of anticancer therapeutics, with more than 50 such agents currently in clinical trials. This Review discusses lessons learned and emerging strategies in the development of ADCs, including aspects such as target selection, the development of warheads, the optimization of linkers and new conjugation chemistries, and provides an overview of agents that are currently in clinical trials.
Abstract | Full Text | PDF
Advances in islet encapsulation technologies
Tejal Desai & Lonnie D. Shea
p338 | doi:10.1038/nrd.2016.232
Islet transplantation can be an effective therapy for patients with type 1 diabetes, but its widespread use is limited by the need for lifelong immunosuppression. Here, Desai and Shea discuss the emerging potential of islet cell encapsulation including new strategies, assess key challenges facing the human translation of this technology and highlight encapsulation devices that have entered the clinic.
Abstract | Full Text | PDF
Targeting phospholipase D in cancer, infection and neurodegenerative disorders
H. Alex Brown, Paul G. Thomas & Craig W. Lindsley
p351 | doi:10.1038/nrd.2016.252
Lipid second messengers such as phosphatidic acid (PtdOH) have a role in a wide range of pathological processes, and phospholipase D (PLD) enzymes are one of the major sources of signal-activated PtdOH generation. In this Review, Brown, Thomas and Lindsley discuss the development of PLD inhibitors, with a focus on isoform-specific inhibitors, and their potential applications in the treatment of cancer, neurodegeneration and infection.
Abstract | Full Text | PDF
Advertisement
nature.com webcasts

Springer Nature presents a custom webcast on: 3D High-Content Screening of Organoids for Drug Discovery. 

Register for FREE

Date: Wednesday 24th May
Time: 8AM PDT | 11AM EDT | 4PM BST | 5PM CEST

Sponsored by: Perkin Elmer 
www.PerkinElmer.com/cellularimaging
Corrigendum: Bracing for the biosimilar wave
Asher Mullard
p367 | doi:10.1038/nrd.2017.64
Full Text | PDF
 
CORRECTIONTop
Advances in islet encapsulation technologies
Tejal Desai & Lonnie D. Shea
p367 | doi:10.1038/nrd.2017.67
Full Text | PDF
Erratum: An audience with Jay Bradner
Asher Mullard
p367 | doi:10.1038/nrd.2017.71
Full Text | PDF
Advertisement
npj Vaccines is an online-only, open access, multidisciplinary journal dedicated to publishing cutting-edge research and development on human and veterinary vaccines. npj Vaccines is now open for submissions.

Explore the benefits of submitting your next manuscript to the journal.
 
nature events
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here.

Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com
More Nature Events

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount
(You will need to log in to be recognised as a nature.com registrant).

For further technical assistance, please contact our registration department

For print subscription enquiries, please contact our subscription department

For other enquiries, please contact our feedback department

Nature Publishing Group | One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA

Nature Publishing Group's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne
San Diego - San Francisco - Washington - New York - Boston

Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at The Campus, 4 Crinan Street, London, N1 9XW.

© 2017 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.

nature publishing group